SERPALAN Drug Patent Profile
✉ Email this page to a colleague
When do Serpalan patents expire, and when can generic versions of Serpalan launch?
Serpalan is a drug marketed by Lannett and is included in one NDA.
The generic ingredient in SERPALAN is reserpine. There are nineteen drug master file entries for this compound. Additional details are available on the reserpine profile page.
Summary for SERPALAN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 101 |
Patent Applications: | 3,250 |
Formulation / Manufacturing: | see details |
DailyMed Link: | SERPALAN at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for SERPALAN
US Patents and Regulatory Information for SERPALAN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lannett | SERPALAN | reserpine | TABLET;ORAL | 010124-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Lannett | SERPALAN | reserpine | TABLET;ORAL | 010124-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |